Minerva Neurosciences Stock (NASDAQ:NERV)
Previous Close
$2.16
52W Range
$2.06 - $13.49
50D Avg
$2.33
200D Avg
$2.67
Market Cap
$14.83M
Avg Vol (3M)
$18.05K
Beta
0.17
Div Yield
-
NERV Company Profile
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
NERV Performance
Peer Comparison
| Ticker | Company |
|---|---|
| BMEA | Biomea Fusion, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| RNAZ | TransCode Therapeutics, Inc. |
| ALXO | ALX Oncology Holdings Inc. |
| CABA | Cabaletta Bio, Inc. |
| INZY | Inozyme Pharma, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| MREO | Mereo BioPharma Group plc |
| EYPT | EyePoint Pharmaceuticals, Inc. |
| ANNX | Annexon, Inc. |
| KOD | Kodiak Sciences Inc. |
| WVE | Wave Life Sciences Ltd. |
| VIRX | Viracta Therapeutics, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| INAB | IN8bio, Inc. |
| LPTX | Leap Therapeutics, Inc. |
| ZURA | Zura Bio Limited |
| TERN | Terns Pharmaceuticals, Inc. |
| EYEN | Eyenovia, Inc. |
| CGTX | Cognition Therapeutics, Inc. |